首页> 外文期刊>Clinical and experimental pharmacology & physiology >Expression and functional role of the RhoA/Rho-kinase pathway in rat coeliac artery.
【24h】

Expression and functional role of the RhoA/Rho-kinase pathway in rat coeliac artery.

机译:RhoA / Rho激酶途径在大鼠腹腔动脉中的表达及其功能作用。

获取原文
获取原文并翻译 | 示例
           

摘要

1. Rho-kinase (ROK) stimulation represents a key step in the maintenance of agonist-induced contraction, an effect counteracted by nitric oxide (NO) released from the endothelium. The aim of the present study was to characterize the involvement of ROK in smooth muscle contraction of the rat coeliac artery using functional and expression studies. 2. Rings of rat coeliac artery were mounted in 5 mL myographs containing warmed and oxygenated Krebs' solution. Rings were connected to isometric transducers and data were recorded in a PowerLab system (ADInstruments, Colorado Springs, CO, USA). After a 60 min equilibration period, preparations were precontracted with phenylephrine (1 micromol/L). Endothelial integrity was assessed by treating the vessels with acetylcholine (1 micromol/L). Expression of ROKalpha, ROKbeta and RhoA was analysed using western blot, whereas Rho guanine nucleotide exchange factors (RhoGEF) were measured at the mRNA level. 3. The addition of Y-27632 (0.01-30 micromol/L) caused sustained relaxation of rings contracted with phenylephrine (PE; 1 micromol/L), with intact or denuded endothelium (pEC(50) = 6.38 +/- 0.03 and 5.65 +/- 0.02, respectively). N(G)-Nitro-l-arginine methyl ester (100 micromol/L) or 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (10 micromol/L), but not indomethacin (10 micromol/L), caused marked rightward shifts of the concentration-response curves to Y-27632. The contractile response to KCl (80 mmol/L) was significantly reduced by Y-27632, with a maximal inhibition of 57 +/- 6%. Nifedipine (0.1-100 nmol/L) fully blocked KCl-evoked contractions, but only marginally affected those in response to PE (27 +/- 2% maximal inhibition). At 1 micromol/L, Y-27632 also significantly enhanced relaxations to sodium nitroprusside (SNP; 0.0001-1 micromol/L). 4. At 1 micromol/L, SNP (but not 1 micromol/L Y-27632) significantly elevated the cGMP content above basal levels. Coincubation with SNP and Y-27632 increased cGMP levels, but the results were not significantly different fromthose in the presence of SNP alone. 5. Western blot analysis revealed the protein expression of RhoA, ROKalpha and ROKbeta. The PDZ-RhoGEF, p115RhoGEF and leukaemia-associated RhoGEF (LARG) mRNA expression in coeliac artery was visualized by electrophoresis on agarose gels. 6. The results clearly demonstrate a role for the RhoA/ROK signalling pathway in the regulation of rat coeliac artery smooth muscle contraction. The findings of the present study suggest that endogenous nitric oxide-induced relaxation is mediated, in part, by inhibition of RhoA/ROK signalling in this tissue.
机译:1. Rho激酶(ROK)刺激是维持激动剂诱导的收缩的关键步骤,这一作用被内皮释放的一氧化氮(NO)抵消。本研究的目的是使用功能和表达研究来表征ROK参与大鼠腹腔动脉平滑肌收缩的过程。 2.将大鼠腹腔动脉环安装在装有加热和充氧的克雷布斯溶液的5 mL肌电描记器中。将环连接到等距传感器,并在PowerLab系统(ADInstruments,科罗拉多州科罗拉多斯普林斯,美国)中记录数据。经过60分钟的平衡后,将制剂与去氧肾上腺素(1 micromol / L)预缩合。通过用乙酰胆碱(1微摩尔/升)处理血管来评估内皮完整性。使用蛋白质印迹分析ROKalpha,ROKbeta和RhoA的表达,而在mRNA水平上测量Rho鸟嘌呤核苷酸交换因子(RhoGEF)。 3.添加Y-27632(0.01-30 micromol / L)会导致与去氧肾上腺素(PE; 1 micromol / L)收缩的环持续松弛,内皮完整或裸露(pEC(50)= 6.38 +/- 0.03,并且分别为5.65 +/- 0.02)。 N(G)-硝基-1-精氨酸甲酯(100 micromol / L)或1H- [1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one(10 micromol / L),但不是吲哚美辛(10 micromol / L)引起浓度响应曲线向Y-27632的明显右移。 Y-27632显着降低了对KCl(80 mmol / L)的收缩反应,最大抑制率为57 +/- 6%。硝苯地平(0.1-100 nmol / L)完全阻断了KCl诱发的收缩,但仅轻微影响那些对PE的反应(最大抑制27 +/- 2%)。在1 micromol / L时,Y-27632还显着增强了对硝普钠(SNP; 0.0001-1 micromol / L)的松弛。 4.在1微摩尔/升下,SNP(而不是1微摩尔/升Y-27632)将cGMP含量显着提高至基础水平以上。与SNP和Y-27632共同孵育可提高cGMP水平,但结果与仅存在SNP时的结果没有显着差异。 5.蛋白质印迹分析揭示了RhoA,ROKalpha和ROKbeta的蛋白质表达。通过在琼脂糖凝胶上电泳观察腹腔动脉中的PDZ-RhoGEF,p115RhoGEF和白血病相关的RhoGEF(LARG)mRNA表达。 6.结果清楚地证明了RhoA / ROK信号传导途径在调节大鼠腹腔动脉平滑肌收缩中的作用。本研究的发现表明,内源性一氧化氮诱导的弛豫部分是通过抑制该组织中的RhoA / ROK信号传导来介导的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号